Restricted accessResearch articleFirst published online 2021-04
Pharmacodynamic Analysis of Meropenem and Fosfomycin Combination Against Carbapenem-Resistant Acinetobacter baumannii in Patients with Normal Renal Clearance: Can It Be a Treatment Option?
Combination therapy may be a treatment option against carbapenem-resistant Acinetobacter baumannii (CR-AB) infections. In this study, we explored the utility of fosfomycin in combination with meropenem (FOS/MEM) against CR-AB isolates.
Materials and Methods:
Screening of synergistic activity of FOS/MEM was performed using the checkerboard assay. A pharmacokinetic/pharmacodynamic analysis was performed for various FOS/MEM regimens using Monte Carlo simulations.
Results:
The minimum inhibitory concentration (MIC) required to inhibit the growth of 50% of the isolates (MIC50) and MIC required to inhibit the growth of 90% of the isolates (MIC90) of FOS and MEM were reduced fourfold and twofold, respectively. The combination was synergistic against 14/50 isolates. No antagonism was observed. Sixteen out of fifty isolates had MEM MICs of ≤8 mg/L when subjected to combination therapy, compared to none with monotherapy. Forty-one out of 50 isolates had FOS MICs of ≤128 mg/L when subjected to combination therapy, compared to 17/50 isolates with monotherapy. The cumulative fraction response for MEM and FOS improved from 0% to 40% and 40% to 80%, with combination therapy, respectively.
Conclusions:
Addition of MEM improved the in vitro activity of FOS against the CR-AB isolates. FOS/MEM could be a plausible option to treat CR-AB for a small fraction of isolates.
Get full access to this article
View all access options for this article.
References
1.
Garza-GonzálezE., Llaca-DíazJ.M, Bosques-PadillaF.J, and GonzálezG.M.. 2010. Prevalence of multidrug-resistant bacteria at a tertiary-care teaching hospital in Mexico: special focus on Acinetobacter baumannii. Chemotherapy, 56:275–279.
2.
Bergogne-BerezinE., and TownerK.. 1996. Acinetobacter spp. as nosocomial pathogens: microbiological,, clinical, and epidemiological features. Clin. Microbiol. Rev. 9:148.
3.
KarageorgopoulosD.E., and FalagasM.E.. 2008. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect. Dis. 8:751–762.
4.
Garnacho-MonteroJ., Ortiz-LeybaC., Fernandez-HinojosaE., Aldabo-PallasT., CayuelaA., Marquez-VacaroJ.A, Garcia-CurielA., and Jimenez-JimenezF.J.. 2005. Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med. 31:649–655.
5.
WałaszekM., RózańskaA., WałaszekM.Z, and Wójkowska-MachJ.. 2018. Epidemiology of ventilator-associated pneumonia, microbiological diagnostics and the length of antimicrobial treatment in the polish intensive care units in the years 2013–2015. BMC Infect. Dis. 18:308.
6.
CisnerosJ.M., and Rodríguez-BañoJ.. 2002. Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment. Clin. Microbiol. Infect. 8:687–693.
7.
ZhengY.L., WanY.F, ZhouL.Y, YeM.L, LiuS., XuC.Q, HeY.Q, and ChenJ.H.. 2013. Risk factors and mortality of patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia. Am. J. Infect. Control, 41:e59–e63.
8.
Mohd Sazlly LimS., SimeF.B, and RobertsJ.A.. 2019. Multidrug-resistant Acinetobacter baumannii infections: current evidence on treatment options and the role of pharmacokinetics/pharmacodynamics in dose optimisation. Int. J. Antimicrob. Agents, 53:726–745.
9.
MenegucciT.C., AlbieroJ., MiglioriniL.B, AlvesJ.L.B, VianaG.F, MazucheliJ., Carrara-MarroniF.E, CardosoC.L, and TognimM.C.B. 2016. Strategies for the treatment of polymyxin B-resistant Acinetobacter baumannii infections. Int. J. Antimicrob. Agents, 47:380–385.
10.
ZhuW., WangY., CaoW., CaoS., and ZhangJ.. 2018. In vitro evaluation of antimicrobial combinations against imipenem-resistant Acinetobacter baumannii of different MICs. J. Infect. Public Health, 11:856–860.
11.
RobertsJ.A., KirkpatrickC.M.J, and LipmanJ.. 2010. Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients. J. Antimicrob. Chemother. 66:227–231.
12.
AlbieroJ., SyS.K, MazucheliJ., Caparroz-AssefS.M, CostaB.B, AlvesJ.L.B, GalesA.C, and TognimM.C.B. 2016. Pharmacodynamic evaluation of the potential clinical utility of fosfomycin and meropenem in combination therapy against KPC-2-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 60:4128–4139.
13.
MenegucciT.C., FedrigoN.H, LodiF.G, AlbieroJ., NishiyamaS.A.B, MazucheliJ., Carrara-MarroniF.E, VoelknerN.M.F, GongH., and SyS.K.. 2019. Pharmacodynamic effects of sulbactam/meropenem/polymyxin-B combination against extremely drug resistant Acinetobacter baumannii using checkerboard information. Microbial. Drug Resist. 25:1266–1274.
14.
ZowawiH.M., SartorA.L, SidjabatH.E, BalkhyH.H, WalshT.R, Al JohaniS.M, AlJindanR.Y, AlfaresiM., IbrahimE., and Al-JardaniA.. 2015. Molecular Epidemiology of carbapenem resistant Acinetobacter baumannii in the gulf cooperation council states. Dominance of OXA-23-type producers. J. Clin. Microbiol. 53:896–903.
15.
European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). 2003. Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by broth dilution. Clin. Microbiol. Infect. 9:ix–xv.
16.
CLSI. 2015. Methods for Dilution Antimicrobial Susceptibility Test for Bacteria That Grow Aerobically; Approved Standard Tenth Edition. CLSI document M07–A10. Clinical and Laboratory Standards Institute, Wayne, PA.
17.
Doern, C.D. 2014. When does 2 + 2 = 5?: a review of antimicrobial synergy testing. J. Clin. Microbiol. 52:4124–4128.
18.
SaimanL.2007. Clinical utility of synergy testing for multidrug-resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis: ‘the motion for’. Paediatr. Respir. Rev. 8:249–255.
19.
ParkerS.L., FrantzeskakiF., WallisS.C, DiakakiC., GiamarellouH., KoulentiD., KaraiskosI., LipmanJ., DimopoulosG., and RobertsJ.A.. 2015. Population pharmacokinetics of fosfomycin in critically ill patients. Antimicrob. Agents Chemother. 59:6471–6476.
20.
AlobaidA.S., WallisS.C, JarrettP., StarrT., StuartJ., Lassig-SmithM., MejiaJ.L.O, RobertsM.S, LipmanJ., and RobertsJ.A.. 2016. Effect of obesity on the population pharmacokinetics of meropenem in critically ill patients. Antimicrob. Agents Chemother. 60:4577–4584.
21.
MouldD., and UptonR.. 2013. Basic concepts in population modeling, simulation, and model-based drug development—part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacom. Syst. Pharmacol. 2:1–14.
22.
GouloozeS.C., VöllerS., VälitaloP.A, CalvierE.A, AaronsL., KrekelsE.H, and KnibbeC.A.. 2019. The influence of normalization weight in population pharmacokinetic covariate models. Clin. Pharmacokinet. 58:131–138.
23.
ZeitlingerM., SauermannR., TraunmüllerF., GeorgopoulosA., MüllerM., and JoukhadarC.. 2004. Impact of plasma protein binding on antimicrobial activity using time–killing curves. J. Antimicrob. Chemother. 54:876–880.
24.
AstraZeneca PharmaceuticalsL. 2013. Merrem® IV (Meropenem for Injection) Package Insert. AstraZeneca Pharmaceuticals LP, Wilmington, DE.
25.
LepakA.J., ZhaoM., VanScoyB., TaylorD.S, Ellis-GrosseE., AmbroseP.G, and AndesD.R.. 2017. In vivo pharmacokinetics and pharmacodynamics of ZTI-01 (fosfomycin for injection) in the neutropenic murine thigh infection model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 61:e00476-17.
26.
MacVaneS.H., CrandonJ.L, and NicolauD.P.. 2014. Characterizing in vivo pharmacodynamics of carbapenems against Acinetobacter baumannii in a murine thigh infection model to support breakpoint determinations. Antimicrob. Agents Chemother. 58:599–601.
27.
NeelyM., van GuilderM., YamadaW., SchumitzkyA., and JelliffeR.. 2012. Accurate detection of outliers and subpopulations with Pmetrics, a non-parametric and parametric pharmacometric modeling and simulation package for R. Ther. Drug Monit. 34:467.
28.
MoutonJ.W., DudleyM.N, CarsO., DerendorfH., and DrusanoG.L.. 2005. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J. Antimicrob. Chemother. 55:601–607.
29.
Clinical and Laboratory Standards Institute. 2020. Performance Standards for Antimicrobial Susceptibility Testing 30th ed. CLSI Supplement M100. 30th ed. Clinical and Laboratory Standards Institute, Wayne PA.
30.
LuC.-L., LiuC.-Y, HuangY.-T, LiaoC.-H, TengL.-J, TurnidgeJ.D, and HsuehP.-R.. 2011. Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods. Antimicrob. Agents Chemother. 55:4295–4301.
31.
FalagasM.E., KastorisA.C, KarageorgopoulosD.E, and RafailidisP.I.. 2009. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int. J. Antimicrob. Agents, 34:111–120.
32.
SarkarP., YarlagaddaV., GhoshC., and HaldarJ.. 2017. A review on cell wall synthesis inhibitors with an emphasis on glycopeptide antibiotics. Medchemcomm. 8:516–533.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
